Brief: Gensight Biologics H1 Operating Income Up At EUR 6.9 Million

Gensight Biologics SA

29/07/2021 06:30

July 29 (Reuters) - GENSIGHT BIOLOGICS SA  SIGHT.AS :
    * H1 OPERATING INCOME EUR 6.9 MILLION VERSUS EUR 3.3 MILLION
YEAR
AGO
    * H1 NET LOSS EUR 8.3 MILLION VERSUS LOSS EUR 14.7 MILLION
YEAR
AGO
    * H1 REVENUES EUR 5.6 MILLION VERSUS EUR 0.7 MILLION YEAR
AGO
    * H1 OPERATING LOSS EUR 6.7 MILLION VERSUS EUR 13.6 MILLION
YEAR
AGO
    * CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2021 AMOUNTED TO
EUR
54.3 MILLION
    * PIONEER PHASE I/II CLINICAL TRIAL OF GS030: CO EXPECTS TO
COMPLETE RECRUITMENT OF EXTENSION COHORT BY END 2021
    * MULTIPLE REGULATORY AND CLINICAL MILESTONES EXPECTED IN Q4
2021
    * SUCCESSFUL REFINANCING IN Q1 2021 SECURES MID-2023 RUNWAY

Source text for Eikon:  ID:nBw7J9154a 
Further company coverage:  SIGHT.AS 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))